Over the past decades, rheumatology has shaped as a rapidly developing scientific discipline with a wide range of interests and evolving priorities. Initial reports on the use of the first generation of biological agents for rheumatoid arthritis and other inflammatory rheumatic diseases in the early 2000s opened up new avenues for research at the interface of immunology, medical chemistry, and rheumatology. By improving the outcomes of suppressing autoimmunity and inflammation, rheumatologists across the world have increased the lifespan of their patients and encountered a number of new challenges. One such challenge is comorbidity, which necessitates multidisciplinary approach to rheumatic diseases, implementation of knowledge and skills from allied fields of science (i.e., cardiology, oncology, hematology). Authors of research studies covering the issue of comorbidity in rheumatic diseases are now targeting not only periodicals in rheumatology but also in allied fields of science with editorial and reviewer boards competent to process multidisciplinary research reports.
ΕΥΡΕΤΉΡΙΑΣΉ ΠΕΡΙΟΔΙΚΏΝ ΡΕΥΜΑΤΟΛΟΓΙΑΣ: Ή ΚΑΛΥΨΉ ΤΏΝ ΚΕΝΏΝ ΣΤΟ ΕΚΔΟΤΙΚΟ ΤΟΠΙΟ INDEXING RHEUMATOLOGY JOURNALS: FILLING GAPS IN THE PUBLISHING LANDSCAPE
With the evolving therapeutic options and changing clinical picture of rheumatic diseases, the mainstream rheumatology periodicals as hubs for scientific evidence are transforming and prioritizing large-scale clinical trials, cohort studies, and practice guidelines of large professional societies. In the era of biological therapy, Annals of the Rheumatic Diseases and Arthritis & Rheumatology have become the big two references for researchers seeking the highest level of evidence in the field. These journals have become influential and increased their impact indices by publishing systematic reviews and guidelines, containing the highest level of evidence and statements of the world's leading professional societies -the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). The two big journals have gradually increased rejection rates of small research reports, case studies, and items of peripheral professional and regional interest, all of which are known to negatively affect the notorious impact factor. 1 In fact, the 12% acceptance rate, which is currently displayed on the website of the Annals of the Rheumatic Diseases, speaks about high selectivity of this journal (http://ard.bmj.com/site/about/). The 'information deluge' and accumulation of evidence, stemming from the latest large multicenter trials and cohort studies, have urged most leading scientists to express their own opinion, synthesize new evidence, and publish review articles, which have educational value and are still highly readable items. 2 As a result, periodicals predominantly publishing reviews have flourished as authoritative sources and have boosted their citation indices. Examples of such influential periodicals are Seminars in Arthritis & Rheumatism, Current Opinion in Rheumatology, and Nature Reviews Rheumatology.
Authors whose original research and reviews are rejected by top-tier rheumatology journals may target lower-rank, indexed, and even unindexed, but still widely visible, valuable sources of evidence. They are advised to familiarize with the potential factors of the global visibility of rheumatology journals ( • Abstract aggregators and database vendors (e.g., EBSCO, ProQuest, OVID)
• National, regional and global libraries (e.g., The British Library, The Library of Congress, National Library of Greece)
automatically processes metadata, abstracts, and fulltexts of individual journals articles. Likewise, references and citations are also tracked and automatic reports on citation metrics and journal ranks are displayed (https://scholar.google.co.uk/citations?view_op=top_ venues&hl=en&vq=med_rheumatology). Google Scholar has major drawbacks, including the lack of selectivity toward the tracked items and citations, making it difficult to synthesize evidence and calculate reliable citation indices by solely relying on this platform. 3, 4 Scopus, as a highly selective and the most comprehensive bibliographic database, offers much more reliable accounts on publications and their citations. The current list of rheumatology journals on the Scopus-based SCImago Journal & Country Rank platform (http://www.scimagojr.com/journalrank.php? area=0&category=2745&country=all&year=2014&orde r=sjr&min=0&min_type=cd) includes citation indices of 57 periodicals. The ranking of the twenty most influential journals in the category, which is based on values of the H index, is presented in Table 2 . Of these, only two 6 Although no updated study is available, it is likely that many valuable articles are increasingly processed and published by allied, general medical, nonrheumatology, and even nonmedical journals. Internal medicine, immunology, laboratory medicine, physical medicine, rehabilitation, orthopedics, sports medicine, pharmacy, pharmacology, and medicinal chemistry are areas where authors often publish their rheumatology articles. Journals of the allied subject categories can be primary and secondary targets for authors, who choose them by searching through multidisciplinary and specialist bibliographic databases. Consequently, editors who aim to attract more submissions should expand indexing of their journals in relevant databases. Admittedly, current research studies in rheumatology are increasingly covering issues of rational pharmacotherapy, toxicology, patients' safety and ecology, risk management, and economic burden of musculoskeletal disorders. The task of journal editors is two-fold: to actively seek submissions on cutting-edge topics and list information about their journals on related databases. Although there is no specifically designed database for rheumatology, many other specialist bibliographic databases may index rheumatology journals either selectively or comprehensively and increase their visibility. Experts recognize the growing global economic burden of rheumatic disorders, which is accompanied by intensified research funding in the developed world. 9 Leading grant funders such as the Welcome Trust now mandate public access to the emerging evidences and sequestrate funds for open-access publishing. In line with this, in 2015, EULAR and the BMJ Group launched a new open-access journal, RMD Open, which has a potential to accommodate the best articles rejected by the subscription journal of the Association. Although the gold open access with article processing charges above £1700 was chosen as a publishing model, it is expected that the journal will rapidly increase submissions of highly citable items from all over the world. RMD Open set an example for other rheumatology associations and publishers aiming to increase the visibility of their research. The launching of new journals or rebranding of old ones points to the fact that there are still gaps in the publishing landscape of rheumatology (Table 3) . To fill these gaps, several national and regional journals have changed their titles and publishing models over the past few years. The most successful example is the APLAR Journal of Rheumatology, the official organ of the Asia 
